<DOC>
	<DOCNO>NCT01054261</DOCNO>
	<brief_summary>The objective study compare pharmacokinetics avanafil subject mild moderate renal impairment ass safety toleration avanafil subject mild moderate renal impairment .</brief_summary>
	<brief_title>To Compare Pharmacokinetics Avanafil Subjects With Mild Moderate Renal Impairment Subjects With Normal Renal Function .</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Adult male subject , 2178 year age , must medically healthy clinically significant screen result ( except subject Groups 2 3 ) . Subjects normal renal function ( Group 1 ) must estimate CLcr ≥80 mL/min . Subjects renal impairment ( Groups 2 3 ) must fulfill additional follow criterion : ( ) Stable renal impairment ; ( b ) Group 2 subject mild renal impairment must CLcr ≥50 &lt; 80 mL/min ( c ) Group 3 subject moderate renal impairment must CLcr ≥30 &lt; 50 mL/min . Major exclusion criterion include : history clinical evidence clinically relevant cardiovascular ( include thromboembolic disorder ) , hepatic , renal ( exception renal insufficiency subject Groups 2 3 ) , hematological , endocrine , pulmonary , gastrointestinal , psychiatric neurological impairment ; clinically significant laboratory abnormality judge Investigator ; systolic blood pressure &lt; 90 &gt; 160 mmHg ; diastolic blood pressure &lt; 50 &gt; 95 mmHg ; allergy previous adverse event PDE5 inhibitor constituent ; use prescription overthecounter drug know interfere metabolism cytochrome P450 3A4 enzyme within 30 day prior Day 1 ; use investigational drug within 30 day prior Day 1 ; use prescription overthecounter drug herbal remedy within 14 day prior Day 1 ; history alcohol drug abuse within 18 month , history smoking within 6 month ; positive breathe alcohol test ; positive cotinine test , positive urine drug screen ( except renally impaired subject follow approval Sponsor ) . Additional exclusion criterion list Section 4.2 .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>avanafil , renal , impairment , TA-1790</keyword>
</DOC>